ESI-09 - CAS 263707-16-0
Catalog number:
263707-16-0
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C16H15ClN4O2
Molecular Weight:
330.77
COA:
Inquire
Targets:
Others
Description:
ESI-09 is a specific exchange protein directly activated by cAMP (EPAC) inhibitor with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively, >100-fold selectivity over PKA.ESI-09 is a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic β cells. EPAC1 plays an important role in pancreatic cancer cell migration and invasion, and thus represents a potential target for developing novel therapeutic strategies for pancreatic cancer.
Publictions citing BOC Sciences Products
  • >> More
Purity:
>98%
Synonyms:
ESI-09
MSDS:
Inquire
1.Epac-inhibitors: facts and artefacts.
Rehmann H1. Sci Rep. 2013 Oct 23;3:3032. doi: 10.1038/srep03032.
cAMP is a universal second messenger. Its signalling is mediated by protein kinase A, Epac and certain types of ion channels in mammalians. cAMP signalling is involved in many physiological processes ranging from vision to the control of insulin secretion, pacemaker activity and gene transcription and therefore selective pharmacological interference is of medical interest. Whereas selective inhibitors of PKA and selective activators of Epac are well established, no inhibitors of Epac were available until recently. Here the action of four of the novel Epac inhibitors was analysed by biophysical means. ESI-05 is confirmed as a selective inhibitor of Epac2. No direct action of Brefeldin A on Epac could be demonstrated. ESI-09 and HJC0197 were found to act as chemicals with general protein denaturing properties and do not act on Epac selectively.
2.Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses.
Gong B1, Shelite T, Mei FC, Ha T, Hu Y, Xu G, Chang Q, Wakamiya M, Ksiazek TG, Boor PJ, Bouyer DH, Popov VL, Chen J, Walker DH, Cheng X. Proc Natl Acad Sci U S A. 2013 Nov 26;110(48):19615-20. doi: 10.1073/pnas.1314400110. Epub 2013 Nov 11.
Rickettsiae are responsible for some of the most devastating human infections. A high infectivity and severe illness after inhalation make some rickettsiae bioterrorism threats. We report that deletion of the exchange protein directly activated by cAMP (Epac) gene, Epac1, in mice protects them from an ordinarily lethal dose of rickettsiae. Inhibition of Epac1 suppresses bacterial adhesion and invasion. Most importantly, pharmacological inhibition of Epac1 in vivo using an Epac-specific small-molecule inhibitor, ESI-09, completely recapitulates the Epac1 knockout phenotype. ESI-09 treatment dramatically decreases the morbidity and mortality associated with fatal spotted fever rickettsiosis. Our results demonstrate that Epac1-mediated signaling represents a mechanism for host-pathogen interactions and that Epac1 is a potential target for the prevention and treatment of fatal rickettsioses.
3.Structure-Activity Relationship Studies of Substituted 2-(Isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl Cyanide Analogues: Identification of Potent Exchange Proteins Directly Activated by cAMP (EPAC) Antagonists.
Ye N1, Zhu Y2, Chen H1, Liu Z1, Mei FC2, Wild C1, Chen H1, Cheng X2, Zhou J1. J Med Chem. 2015 Aug 13;58(15):6033-47. doi: 10.1021/acs.jmedchem.5b00635. Epub 2015 Jul 16.
Exchange proteins directly activated by cAMP (EPAC) as guanine nucleotide exchange factors mediate the effects of the pivotal second messenger cAMP, thereby regulating a wide variety of intracellular physiological and pathophysiological processes. A series of novel 2-(isoxazol-3-yl)-2-oxo-N'-phenyl-acetohydrazonoyl cyanide EPAC antagonists was synthesized and evaluated in an effort to optimize properties of the previously identified high-throughput (HTS) hit 1 (ESI-09). Structure-activity relationship (SAR) analysis led to the discovery of several more active EPAC antagonists (e.g., 22 (HJC0726), 35 (NY0123), and 47 (NY0173)) with low micromolar inhibitory activity. These inhibitors may serve as valuable pharmacological probes to facilitate our efforts in elucidating the biological functions of EPAC and developing potential novel therapeutics against human diseases. Our SAR results have also revealed that further modification at the 3-, 4-, and 5-positions of the phenyl ring as well as the 5-position of the isoxazole moiety may allow for the development of more potent EPAC antagonists.
4.cAMP controls the restoration of endothelial barrier function after thrombin-induced hyperpermeability via Rac1 activation.
Aslam M1, Tanislav C2, Troidl C1, Schulz R3, Hamm C1, Gündüz D1. Physiol Rep. 2014 Oct 24;2(10). pii: e12175. doi: 10.14814/phy2.12175. Print 2014 Oct 1.
Inflammatory mediators like thrombin disrupt endothelial adherens junctions (AJs) and barrier integrity leading to oedema formation followed by resealing of AJs and a slow recovery of the barrier function. The molecular mechanisms of this process have not yet been fully delineated. The aim of the present study was to analyse the molecular mechanism of endothelial barrier recovery and thrombin was used as model inflammatory mediator. Thrombin caused a strong increase in endothelial permeability within 10 min accompanied by loss of Rac1 but not cdc42 activity, drop in cellular cAMP contents, and a strong activation of the endothelial contractile machinery mainly via RhoA/Rock signalling. Activation of RhoA/Rock signalling precedes and is dependent upon a rise in the cytosolic Ca(2+) concentration. Inhibition of cytosolic Ca(2+) rise but not MLCK or Rock enhances the recovery of endothelial barrier function. The cellular cAMP contents increased gradually during the barrier recovery phase (30-60 min after thrombin challenge) accompanied by an increase in Rac1 activity.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 61281-37-6 Schisandrin B

Schisandrin B
(CAS: 61281-37-6)

Schisandrin B(Wuweizisu-B) is a dibenzocyclooctadiene derivative isolated from Fructus Schisandrae, has been shown to produce antioxidant effect on rodent liver...

CAS 362003-83-6 NVP-231

NVP-231
(CAS: 362003-83-6)

NVP-231 is a potent, specific, and reversible CerK inhibitor that competitively inhibits binding of ceramide to CerK. NVP-231 is active in the low nanomolar ran...

CAS 2167-85-3 Pipazetate

Pipazetate
(CAS: 2167-85-3)

Pipazetate, as a cough suppressant, is a non-narcotic oral antitussive agent acting centrally on the medullary cough center.

CAS 98753-19-6 Cefpirome Sulfate

Cefpirome Sulfate
(CAS: 98753-19-6)

Cefpirome Sulfate is a fourth generation cephalosporin antibiotic. It was developed by German company Hoechst and France Roussel company together.

CAS 28448-85-3 Bavachalcone

Bavachalcone
(CAS: 28448-85-3)

Bavachalcone inhibited osteoclast formation from precursor cells with the IC(50) of approximately 1.5 microg ml(-1). The activation of MEK, ERK, and Akt by rece...

CAS 3624-96-2 Bialamicol hydrochloride

Bialamicol hydrochloride
(CAS: 3624-96-2)

Bialomicol is a synthetic bio-active chemical.

MK-0493
(CAS: 455957-71-8)

MK-0493 is a novel, potent, and selective agonist of MC4R( melanocortin receptor 4) , which is one of the best-validated genetic targets and considered one of t...

Gemilukast disodium salt
(CAS: 1232861-64-1)

CAS 142227-49-4 4'-Hydroxyphenyl carvedilol

4'-Hydroxyphenyl carvedilol
(CAS: 142227-49-4)

4'-Hydroxyphenyl carvedilol, as a metabolite of Carvedilol it is a nonselective beta blocker/alpha-1 blocker.

CAS 122018-58-0 PLP(139-151)

PLP(139-151)
(CAS: 122018-58-0)

PLP(139-151), a synthetic myelin proteolipid protein (PLP) fragment, induces experimental autoimmune encephalomyelitis (EAE).

CAS 391610-37-0 MCHr1 antagonist 1

MCHr1 antagonist 1
(CAS: 391610-37-0)

A selective antagonist of melanin concentrating hormone-1 (MCH1) receptor

CAS 1435467-38-1 PF-1355

PF-1355
(CAS: 1435467-38-1)

PF-1355 is a selective, mechanism-based inhibitor of myeloperoxidase (MPO) (IC50 = 1.5 μM in LPS-stimulated human whole blood) with excellent selectivity for MP...

CAS 6893-02-3 3,3,5-Triiodo-L-thyronine

3,3,5-Triiodo-L-thyronine
(CAS: 6893-02-3)

3,3,5-Triiodo-L-thyronine(T3), an active metabolite of Thyroxine, could be effective in agonizing both thyroid hormone receptors TRα and TRβ so that might help ...

BPH-652
(CAS: 157124-84-0)

BPH-652, also known as BMS-187745, has been found to be a SQS inhibitor that could probably be effective against S. aureus infections.

CGP 71683 hydrochloride
(CAS: 192322-50-2)

CGP 71683 hydrochloride is a highly selective non-peptide antagonist of the NPY Y(5) receptor (IC50= 1.4 nM) with > 1000-fold selectivity over Y1 (IC50= 2765 nM...

CAS 491-54-3 Kaempferide

Kaempferide
(CAS: 491-54-3)

Kaempferide is an O-methylated flavonol. It can be found in Kaempferia galanga (aromatic ginger). The enzyme kaempferol 4'-O-methyltransferase uses S-adenosyl-L...

CAS 300762-25-8 Hydrocarbon chain derivative 1

Hydrocarbon chain derivative 1
(CAS: 300762-25-8)

Hydrocarbon chain derivative 1 shows inhibitory effect on lipid synthesis (IC50= 11 μM).

CAS 3734-80-3 Ocaphane

Ocaphane
(CAS: 3734-80-3)

Ocaphane is a strong antitumor agent used on a number of animal tumors along with fairly toxic to hemopoietic organs.

CAS 42017-89-0 Fenofibric acid

Fenofibric acid
(CAS: 42017-89-0)

Fenofibric acid is a lipid regulating agent available as delayed release capsules for oral administration.

Aluminum phthalocyanine tetrasulfonate t
(CAS: 118887-28-8)

Aluminum phthalocyanine disulfonate is a mixture of regional isomers, in which sulfonate group can be in 3- or 4- position of phenyl ring. It is a potent photos...

Chemical Structure

CAS 263707-16-0 ESI-09

Quick Inquiry

Verification code

Featured Items